|| List of recent Nucleotide-related patents
|Methods and compositions for transgenic plants with enhanced resistance to biotic and abiotic stress|
The present invention provides methods and compositions for producing transgenic plants having increased resistance to biotic and/or abiotic stress and comprising an exogenous nucleotide sequence encoding a cysteine protease inhibitor.. .
|Regulatory polynucleotides and uses thereof|
The present disclosure provides compositions and methods for regulating expression of transcribable polynucleotides in plant cells, plant tissues, and plants. Compositions include regulatory polynucleotide molecules capable of providing expression in plant tissues and plants.
|Methods and compositions for targeted polynucleotide modification|
A variety of methods and compostions are provided, including methods and compositions for targeted modification of a specific target site in a cell or organism, methods for integrating polynucleotides of interest, methods to assess promoter activity, directly select transformed organisms, minimize or eliminate expression resulting from random integration into the genome of an organism, such as a plant, remove polynucleotides of interest, combine multiple transfer cassettes, invert or excise a polynucleotide, silence a gene, and identify and/or characterize transcriptional regulating regions. The methods involve the introduction of a cell proliferation factor and a double-strand break-inducing enzyme into an organism..
|Novel low molecular weight cationic lipids for oligonucleotide delivery|
The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
|Short interfering rna (sirna) analogues|
The present invention is directed to novel double-stranded short interfering (sirna) analogues comprising locked nucleic acid (lna) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as rna interference (rnai).
|Fusion protein containing a single-stranded dna binding protein and methods for expression and purification of the same|
The present invention provides an expression vector comprising a promoter and a polynucleotide sequence encoding a fusion protein. The present invention further provides a method for purification of an interest protein.
|Ngf aptamer and application thereof|
N31-n32-n33-n34-n35-n36-n37-n38-n39 and n41-n42-n43-n44-n45-n46-n47-n48-n49 are nucleotide sequences capable of forming a stem structure in combination.. .
|Serpina1 sirnas: compositions of matter and methods of treatment|
The technology described herein relates to double-stranded ribonucleic acid (dsrna) compositions targeting the serpinal gene, and methods of using such dsrna compositions to inhibit expression of serpinal. In one embodiment, an irna for inhibiting expression of a serpinal gene includes at least two sequences that are complementary to each other.
|Methods for treating neural cell swelling|
A composition comprising a novel ca2+-activated, [atp]i-sensitive nonspecific cation (ncca-atp) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [ca]i.
|Composition for treatment or prevention of erectile dysfunction including dkk2 protein or dkk2 gene thereof and use of the composition|
A pharmaceutical composition for regenerating an endothelial cell which includes as an active ingredient a dkk2 protein or a polynucleotide encoding the dkk2 protein, a pharmaceutical composition for preventing or treating erectile dysfunction, a method of regenerating an endothelial cell of a subject and a method of preventing or treating erectile dysfunction of a subject and which treat or prevent erectile dysfunction in a subject.. .
|Template directed split and mix synthesis of small molecule libraries|
The invention combines the advantages of split and mix synthesis with the advantages of template directed synthesis. The method comprises the steps of a) adding a linker molecule l to one or more reaction wells; b) adding a molecule fragment to each of said reaction wells; c) adding an oligonucleotide identifier to each of said reaction wells; d) subjecting said wells to conditions sufficient to allow said molecule fragments and said oligonucleotide identifiers to become attached to said linker molecule, or conditions sufficient for said molecule fragments to bind to other molecule fragments and sufficient for said oligonucleotide identifiers to bind to other oligonucleotide identifiers; e) combining the contents of said one or more reaction wells; and f) contacting the resulting bifunctional molecule(s) of step e) with one or more (oligonucleotide) templates each capable of hybridizing to at least one of the oligonucleotide identifiers added step c)..
|Nucleic acid linker|
A nucleic acid linker is for producing a complex of mrna and a protein encoded by that mrna, comprising one 3′-terminal region and two branched 5′-terminal regions, wherein the 3′-terminal region comprises a single-stranded polynucleotide segment able to hybridize with the sequence on the 3′-terminal side of the mrna, and an arm segment that branches off from the single-stranded polynucleotide segment and has a linking segment with the protein on the terminal thereof, and one of the two 5′-terminal regions has a binding site with the 3′-terminal of the mrna.. .
|Polynucleotide barcode generation|
The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing. Such polynucleotide processing may be useful for a variety of applications, including polynucleotide sequencing.
|Enhanced throughput mineral coatings for optimization of stem cell behavior|
Disclosed are methods for cell transfection and regulating cellular behavior. More particularly, the present disclosure relates to methods of non-viral cell transfection and regulating cellular behavior using mineral coatings that allow for the enhanced transfection of cells.
|Detection and quantification of biomolecules using mass spectrometry|
The present invention is directed in part to a method for detecting a target nucleic acid using detector oligonucleotides detectable by mass spectrometry. This method takes advantage of the 5′ to 3′ nuclease activity of a nucleic acid polymerase to cleave annealed oligonucleotide probes from hybridized duplexes and releases labels for detection by mass spectrometry.
|Systems and methods for genetic and biological analysis|
The invention relate to systems and methods for sequencing polynucleotides, as well as detecting reactions and binding events involving other biological molecules. The systems and methods may employ chamber-free devices and nanosensors to detect or characterize such reactions in high-throughput.
|Compositions and methods for conferring herbicide resistance|
The present invention provides a protein, specifically parietochloris incisa acetohydroxyacid synthase, and methods for producing branched-chain amino acid in a cell. The present invention further provides polypeptides and polynucleotides useful for conferring herbicide resistance in a cell or an organism.
|Methods for enhancing genome stability and telomere elongation in embryonic stem cells|
The disclosure provides methods for increasing genome stability of an embryonic stem (es) cell or induced pluripotent stem (ips) cell, increasing telomere length in an es or ips cell, or both, for example by contacting an es or ips cell with an agent that increases expression of zscan4 in the cell. Methods for increasing genome stability or increasing telomere length in a population of es or ips cells are provided, for example by selecting zscan4+ es or ips cells from the population of es or ips cells (which can include both zscan4+ and zscan4− es or ips cells).
|Method to trigger rna interference|
A method to generate sirnas in vivo is described, as are constructs and compositions useful in the method. The method does not depend on the use of dna or synthetic constructs that contain inverted duplications or dual promoters so as to form perfect or largely double-stranded rna.
|Synthetic single chain variable domain (scfv) immunoglobulin fragment vehicle containing fusion proteins for targeted introduction of sirna|
A fusion protein and process are provided by which double-stranded rna containing small interfering rna nucleotide sequences is introduced into specific cells and tissues. A cell surface receptor specific synthetic single chain variable domain (scfv) immunoglobulin fragment vehicle specific to a cell surface receptor of the cell and having a cell surface receptor specific binding site is provided.
|Phosphatidic acid phosphatase gene|
The present invention provides a novel phosphatidic acid phosphatase gene. The object of the present invention can be solved by providing a nucleic acid comprising the nucleotide sequence set forth in seq id no: 1, seq id no: 4, or seq id no: 5; a protein comprising the amino acid sequence set forth in seq id no: 2; and mutants thereof..
|Mutant rb69 dna polymerase|
Provided herein are mutant dna-dependent polymerases which are derived from, or otherwise related to, wild type rb69 dna polymerase. These mutant polymerases are capable of selectively binding labeled nucleotides.
|Methods for improving malic acid production in filamentous fungi|
The present invention relates to methods of producing a c4 dicarboxylic acid, comprising: (a) cultivating a filamentous fungal host cell comprising a polynucleotide selected from the group consisting of a heterologous first polynucleotide encoding a c4 dicarboxylic acid transporter, a heterologous second polynucleotide encoding a malate dehydrogenase, and a heterologous third polynucleotide encoding a pyruvate carboxylase; wherein the filamentous fungal host cell is capable of secreting increased levels of the c4 dicarboxylic acid compared to the filamentous fungal host cell without the heterologous polynucleotide when cultivated under the same conditions; and (b) recovering the c4 dicarboxylic acid. The present invention also relates to methods for increasing c4 dicarboxylic acid production, filamentous fungal host cells and malate dehydrogenase variants..
|Variants of glycerol dehydrogenase having d-lactate dehydrogenase activity and uses thereof|
The present invention provides methods of designing and generating glycerol dehydrogenase (glydh) variants that have altered function as compared to a parent polypeptide. The present invention further provides nucleic acids encoding glydh polypeptide variants having altered function as compared to the parent polypeptide.
|Polypeptides having peroxygenase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Polypeptides having endoglucanase activity and polynucleotides encoding same|
Provided are isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Alpha-amylase variants and polynucleotides encoding same|
The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants..
|Polypeptides having cellobiohydrolase activity and polynucleotides encoding same|
Disclosed are isolated polypeptides having cellobiohydrolase activity, catalytic domains, carbohydrate binding domains and polynucleotides encoding the polypeptides, catalytic domains or carbohydrate binding domains. Furthermore, nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or carbohydrate binding domains are disclosed..
|Nucleotide transient binding for sequencing methods|
Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (snp) analyses.
|Oligonucleotide sequences that identify species of animal|
The present invention provides a method for identifying animal species, said method comprises a step of amplifying a dna fragment by pcr using a dna in a sample as a template and animal-specific dna sequences as a primer pair, wherein the animal-specific dna sequences are derived from a atp synthase subunit 8 gene or a region proximal thereto of a mitochondrial genome; and a step of detecting the amplified dna fragment.. .
|Mutation detection assay|
A method of sample analysis is provided. In certain embodiments, the method involves: a) amplifying a product from a sample that comprises both wild type copies of a genomic locus and mutant copies of the genomic locus that have a point mutation relative to said wild type copies of the genomic locus, to produce an amplified sample, where: i.
|Methods and compositions for inhibiting undesired cleaving of labels|
The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods.
|Coenzyme-linked glucose dehydrogenase and polynucleotide encoding the same|
The present invention provides members that produce on a large scale a coenzyme-linked glucose dehydrogenase which has excellent substrate-recognizing ability toward glucose while providing low action on maltose. The present invention relates to a polynucleotide encoding a soluble coenzyme-linked glucose dehydrogenase that catalyzes the oxidation of glucose in the presence of an electron acceptor and has an activity toward maltose of 5% or lower; a polypeptide encoded by the nucleotide sequence of the polynucleotide; a recombinant vector carrying the polynucleotide; a transformed cell produced using the recombinant vector; a method for producing a polypeptide comprising culturing the transformed cell and collecting from the cultivated products a polypeptide that links to fad to exert the glucose dehydration activity; a method for determination of glucose using the polypeptide; a reagent composition for determination of glucose; and a biosensor..
|Vaccine composition for mucosal administration|
The present invention provides a vaccine composition which comprises a cellular immunity induction promoter universally usable against various antigens in cellular immunity induction by mucosal administration of the antigen and exerts a high cellular immunity inducing effect by mucosal administration. The present invention provides a vaccine composition for mucosal administration to induce cellular immunity, comprising: (i) an antigen; and (ii) one or more cellular immunity induction promoters selected from the group consisting of a tlr ligand, a cyclic dinucleotide, a helper peptide and an immunomodulatory small molecule drug..
|Methods of promoting immune tolerance|
Compositions including a polynucleotide combined with a vehicle and methods of their use to induce a suppressive immune response are provided. In some embodiments the compositions induce an increase in expression of indoleamine 2,3 dioxygenase (ido) enzyme activity in cells.
|H5 proteins of h5n1 influenza virus for use as a medicament|
The present invention is based on the surprising finding that h5 protein of clade 1 h5n1 induces, in particular by a single-shot vaccination, a cross-clade protective immune response to influenza viruses with h5n1 ha. In one aspect, the invention is thus directed to h5 protein of clade 1 h5n1 virus for use in a method of treating or preventing infections with h5n1 virus of a different clade, wherein the h5n1 virus of a different clade comprises a particular polynucleotide and/or h5 protein..
|Infectious clones of torque teno virus|
The present invention is directed to novel nucleotide and amino acid sequences of torque teno virus (“ttv”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine ttv genotypes and isolates.
|Porcine parvovirus 5b, methods of use and vaccine|
The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5b (ppv5b) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus..
|Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury|
Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein said transgenic non-human mammal has a baseline blood platelet count corresponding to a physiological blood platelet count of a matched non-transgenic non-human mammal.
The invention relates generally to polypeptides, such as antibody molecules, that demonstrate high stability and solubility. In particular, the invention relates to polypeptides comprising paired vl and vh domains that demonstrate soluble expression and folding in a reducing or intracellular environment.
|Treatment of neurological conditions|
The present invention is directed to a method for treating an inflammatory neurodegenerative condition of the cns in a subject comprising administering to said subject a g-csf or g-csfr inhibiting agent selected from the group consisting of an antibody specific for g-csf, a soluble g-csfr or a g-csf-binding portion thereof and a 20 to 30 nucleotide sense or antisense molecule targeted to a nucleic acid molecule encoding g-csf.. .
|Method for therapeutic angiogenesis|
The present invention relates to the e2epf ucp-vhl interaction and the uses thereof, more precisely a method for increasing or reducing vhl activity or level by regulating ucp activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of ucp activity is accomplished by any ucp activity inhibitor selected from a group consisting of a small interfering rna (rnai), an antisense oligonucleotide, and a polynucleotide complementarily binding to mrna of ucp, a peptide, a peptide mimetics and an antibody, and a low molecular compound.
|Novel nylanderia fulva virus|
At least one novel virus capable of infecting crazy ants (nylanderia fulva) is isolated, along with polynucleotide sequences and amino acid sequences of the virus. The virus is capable of be used as a biopesticide to control populations of crazy ants..
|Oncolytic viruses and methods for treating neoplastic disorders|
The disclosure provides mutant ribonucleotide reductase strains of poxviruses including for example vaccinia viruses. The disclosure also provides methods and for the use of these mutant ribonucleotide reductase strains of vaccinia viruses in oncolytic virotherapy..
|Remote assembly of targeted nanoparticles using complementary oligonucleotide linkers|
The present invention provides targeted delivery compositions and their methods of use in treating and diagnosing a disease state in a subject. Components of the targeted delivery compositions are put together through duplex formation between oligonucleotides..
|J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use|
In one embodiment, a minibody monomer that binds psma is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from n-terminus to c-terminus, an scfv sequence that can bind psma, an artificial hinge sequence, and a human igg ch3 sequence.